- Open Access
Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations
- Alessia Nasca1,
- Teresa Rizza2,
- Mara Doimo3, 4,
- Andrea Legati1,
- Andrea Ciolfi5,
- Daria Diodato2,
- Cristina Calderan3, 4,
- Gianfranco Carrara1,
- Eleonora Lamantea1,
- Chiara Aiello2,
- Michela Di Nottia2,
- Marcello Niceta5,
- Costanza Lamperti1,
- Anna Ardissone6,
- Stefania Bianchi-Marzoli7,
- Giancarlo Iarossi8,
- Enrico Bertini2,
- Isabella Moroni6,
- Marco Tartaglia5,
- Leonardo Salviati3, 4,
- Rosalba Carrozzo†2 and
- Daniele Ghezzi†1Email authorView ORCID ID profile
© The Author(s). 2017
- Received: 5 January 2017
- Accepted: 24 April 2017
- Published: 12 May 2017
Heterozygous mutations in OPA1 are a common cause of autosomal dominant optic atrophy, sometimes associated with extra-ocular manifestations. Few cases harboring compound heterozygous OPA1 mutations have been described manifesting complex neurodegenerative disorders in addition to optic atrophy.
We report here three patients: one boy showing an early-onset mitochondrial disorder with hypotonia, ataxia and neuropathy that was severely progressive, leading to early death because of multiorgan failure; two unrelated sporadic girls manifesting a spastic ataxic syndrome associated with peripheral neuropathy and, only in one, optic atrophy. Using a targeted resequencing of 132 genes associated with mitochondrial disorders, in two probands we found compound heterozygous mutations in OPA1: in the first a 5 nucleotide deletion, causing a frameshift and insertion of a premature stop codon (p.Ser64Asnfs*7), and a missense change (p.Ile437Met), which has recently been reported to have clinical impact; in the second, a novel missense change (p.Val988Phe) co-occurred with the p.Ile437Met substitution. In the third patient a homozygous mutation, c.1180G > A (p.Ala394Thr) in OPA1 was detected by a trio-based whole exome sequencing approach. One of the patients presented also variants in mitochondrial DNA that may have contributed to the peculiar phenotype.
The deleterious effect of the identified missense changes was experimentally validated in yeast model. OPA1 level was reduced in available patients’ biological samples, and a clearly fragmented mitochondrial network was observed in patients’ fibroblasts.
This report provides evidence that bi-allelic OPA1 mutations may lead to complex and severe multi-system recessive mitochondrial disorders, where optic atrophy might not represent the main feature.
- Optic atrophy
- Mitochondrial disorder
- Recessive trait
- Targeted resequencing
Optic Atrophy 1 (OPA1, OMIM*605290) is a dynamin-related protein of the large GTPase superfamily that locates to the inner mitochondrial membrane and is involved in mitochondrial dynamics and mtDNA maintenance.
Pathogenic mutations in the OPA1 gene have largely been associated with autosomal dominant optic atrophy (ADOA; OMIM#165500), a visual disorder associated with degeneration of retinal ganglion cells. Its prevalence is estimated at 1/50,000. Classical ADOA typically has early onset, before 10 years of age, and manifests with various levels of visual impairment: bilateral visual loss, dyschromatopsia, centrocecal scotomas and temporal optic disc atrophy. Up to 20% of OPA1-mutated patients also develop additional more complex neurodegenerative disorder with extra-ocular manifestations, including deafness , chronic progressive external ophthalmoplegia, ptosis, ataxia, peripheral neuropathy and mitochondrial myopathy with multiple mtDNA deletions, leading to a syndromic disease sub-group known as ‘ADOA plus’ (OMIM#125250) [2, 3].
To date, over 300 mutations in OPA1 have been identified and associated with ADOA and ADOA plus. Half of these variants are predicted to result in a truncated protein producing haploinsufficiency and are usually linked to the classical non-syndromic form of ADOA. The ‘ADOA plus’ phenotype is often associated with dominant missense mutations in OPA1 . In a few cases, the phenotype is due to compound heterozygous OPA1 mutations preserving transcript expression , and suggestive of recessive or semi-dominant patterns of inheritance [3–5]. Recently, compound heterozygous mutations in OPA1 have been associated with Behr syndrome (OMIM#210000), a disease characterized by the association of early-onset optic atrophy with spinocerebellar degeneration [6, 7]. Finally, the first homozygous OPA1 mutation has just been reported, associated with fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy . The clinical spectrum of these emerging double-mutant OPA1-related disorders remains to be fully characterized.
We report here three patients with biallelic OPA1 mutations: a boy showing an early-onset and severely progressive mitochondrial disorder and two girls showing a spastic ataxic syndrome associated with sensory motor peripheral neuropathy, resembling Behr syndrome.
Total DNA was extracted from muscle, peripheral blood lymphocytes, fibroblasts from patients and relatives using standard methods. Sequencing of the entire mitochondrial DNA (mtDNA) was performed essentially as previously described . mtDNA content was evaluated by real-time PCR-based quantification (ABI7000 Real-Time PCR System) using specific mtDNA probes (amplicons nt 867-928, 12835-12893) and a standard, single-copy autosomal gene (RNaseP) .
For Patients1 and 2, NGS library preparation, sequencing, alignment and variant calling were performed as recently described . Filtering was carried out by applying a series of steps: low-quality variants were filtered out (Illumina Qscore threshold of 20); variants with a minor allele frequency (MAF) >1% in the 1000 Genomes Project (http://www.1000genomes.org), Exome Variant Server (http://evs.gs.washington.edu) and Exome Aggregation Consortium (ExAC: http://exac.broadinstitute.org) databases were discharged; finally, we focused on predicted missense, frame-shift, stop-gain or stop-loss, and splice-site variants.
For proband 3, targeted enrichment and massively parallel sequencing were performed on genomic DNA of the affected subject and their parents. Exome capture was carried out using SureSelect Human All Exon V.4 (Agilent). Sequencing data analysis was performed using an in-house implemented pipeline which mainly takes advantage of the Genome Analysis Toolkit (GATK V.3.5) framework , as previously reported [13–15]. Quality filtering of variants were as previously reported , and high-quality variants were filtered against public (dbSNP146 and ExAC V.0.3) and in-house (approx. 600 population-matched WES) databases to retain private, rare (MAF <0.1%) and clinically associated variants, which were filtered to retain only those located in exons with any effect on the coding sequence, and splice site regions (variants located from −3 to +8 with respect to an exon-intron junction). Functional annotation of variants was performed using SnpEff V.4.2 and dbNSFP V.2.9 [17–19]. WES statistics are reported in Additional file 1. Functional impact of variants was analyzed by Combined Annotation Dependent Depletion (CADD) V.1.3 and dbNSFP Support Vector Machine (SVM) V.2.9 algorithms [18, 19]. Variant prioritization was performed by GeneDistiller . All variants identified by NGS were validated by Sanger sequencing.
RNA was extracted from skin fibroblasts and 1 μg was used as template for reverse transcriptase PCR (RT-PCR) to obtain full-length cDNA. OPA1 transcript was amplified and PCR products were sequenced in order to confirm genomic variants and unmask potential events of nonsense mediated decay.
A hybrid gene was obtained by joining the 5' portion of the yeast MGM1 gene (the orthologous of human OPA1), encoding the mitochondrial targeting sequence and the transmembrane domain, to the 3' of the human OPA1 cDNA using a sequential PCR protocol. Primers and conditions are available upon request. The resulting construct was then cloned into the pCM184 yeast expression vector. Individual mutants were generated by site-specific mutagenesis.
Yeast strains, media, growth conditions, and the whole procedure for selection of haploid cells have been previously reported in detail . Briefly, a single copy of the MGM1 gene was inactivated in wild type diploid W303 yeast by homologous recombination with a KANMX4 cassette. Heterozygous strains were transformed with either the wild type or one of the mutant constructs and, after sporulation, haploid yeast harboring the mutant MGM1 gene and the plasmid of interest were selected and used for subsequent experiments.
Fibroblasts were pelleted and solubilized in RIPA buffer with protease inhibitors. 50 μg of proteins were loaded for each sample in 10% denaturing sodium-dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
The following antibodies were used: OPA1 (monoclonal antibody BD Biosciences), NDUFA9 (MitoSciences), MTCO2 (MitoSciences), porin/VDAC (MitoSciences), beta-tubulin/TUBB (Sigma-Aldrich), and HSP60 (Abcam).
Skin fibroblasts from patients and controls were cultured in a 37 °C incubator with 5% CO2, in either 25 mM glucose or 5 mM galactose DMEM (Euroclone) supplemented with 10% FBS, 1% L-glutamine, and 0.2% sodium pyruvate. For visualization of the mitochondrial network, the mitochondrial fluorescent dye MitoTracker Red-CMXRos (Invitrogen) was added to the culture media at final concentrations of 50 nM for 30 min and then visualized by fluorescence microscopy. Images for P1 were acquired with a confocal microscope (Leica TSC-SP8) and for P3 with inverted microscope (Leica DMi8).
Complex V activity was measured in fibroblast mitochondria of P3 and age-matched controls, using reported spectrophotometric methods . Either succinate (the direct substrate of complex II-succinate dehydrogenase), or malate and pyruvate + malate (which generate NADH, substrate of complex I-NADH dehydrogenase) were used as substrates. Cellular ATP content was assayed luminometrically using the ATPLite 1 Step (PerkinElmer, Boston) according to the procedure recommended by the manufacturer and using 2 × 104 cells. Aged matched controls have been used in three different experiments, either in a regular medium as well as in a galactose-supplemented medium (5 mM). Luminescence was measured using the EnSpire Multimode Plate Readers (PerkinElmer).
Electroretinogram (ERG): Retimax instrument (CSO, Firenze, Italy) was used for the full-field flash ERG and pattern VEP assessment in the protocol session. The cornea was anesthetized with 1% dicaine. HKloops ring fiber electrodes were used to record ERGs. A small Ag/AgCl skin earth electrode was placed at the center of the forehead. Mesopic and photopic stimuli were used for recording sessions.
Visual evoked potential (VEP): Visual stimuli consisted of checkerboard patterns (a single check edge subtending 60 and 15 min of arc; contrast 99%; mean luminance 60 cd/m2) generated on a monitor subtending 26° and reversed in contrast at the rate of two reversal per second. The stimulation was monocular, with full occlusion of the fellow eye. To maintain stable fixation, a small red target was (0.5°) was placed in the center of the stimulation field. VEPs were recorded by cup-shaped Ag/AgCl electrodes placed over the scalp two cm above the inion (Oz) with the reference in Fpz and the ground on the mastoid. The time-to-peak (in milliseconds) and peak-to-peak amplitude (in microvolts) of major VEP components (i.e. N75, P100 and N145) were measured.
Optical coherence tomography (OCT)
Peripapillar retinal nerve fiber layer (RNFL) thickness was measured with a spectral-domain (SD)-OCT (Optos SD-OCT, Glasgow, UK). All scans were done using an internal fixation target in the OCT device. The fast RNFL scan protocol consisted of three consecutive 360° circular scans with a diameter of 3.4 mm centered on the optic disc. Parameters including average RNFL thickness in four quadrants were generated automatically in the analysis report and compared to control values. Each sector was coded in green, yellow, or red for RNFL measurement greater than the lower 95th percentile, less than the lower 95th percentile, or less than the lower 99th percentile range, respectively. All images had signal strength of at least 7. Images with motion artifacts were discarded and rescanned.
P1. The proband P1 (II-2) is a boy, second child from unrelated parents.
His older brother (II-1) was affected by a neurological disease for which a metabolic etiology was suspected but never confirmed. In II-1, psychomotor delay was reported since first age of life, and he never achieved sitting or standing position. At 9 months of age the presence of ptosis and ophthalmoparesis was depicted, with normal fundus exam. Neurological evaluation at the age 2.5 years showed poor somatic growth (10%ile), microcephaly (<3%ile), hypotonia, ataxia and mental retardation. The following exams resulted normal: plasma lactate, organic acids, amino acids, mucopolysaccharides, oligosaccharides; no brain MRI was available. The sibling II-1 died at age 2 years and 10 months with multiorgan failure during a septic shock due to paralytic ileus. No biological material was available from this individual.
P2. The proband P2 is the only child of unrelated parents of Italian origins. Family history was negative: mother presents severe myopia without optic atrophy or any neurological sign. P2 was born at term after an uncomplicated pregnancy and delivery. Psychomotor development was referred normal. Between ages 4 and 6 years, she presented worsening of her visual acuity. Bilateral optic neuropathy was diagnosed with normal ERG but altered VEPs. She underwent to ophthalmologic follow-up (instrumental data not available). She arrived at our observation at 14 years of age. Neurological evaluation showed mild bilateral ptosis and strabismus, dysdiadochokinesia, dysmetria, mild ataxia and pes cavus; tendon reflexes were absent. Cognitive functions were normal. Fundoscopy and VEPs confirmed optic atrophy; ERG was normal; SAPs and BAEPs showed central conduction abnormalities. Brain MRI disclosed optic nerves and chiasm atrophy. Electroneuronography revealed an axonal sensory neuropathy. Electroencephalography was normal. Plasmatic lactate levels were normal. Treatment with idebenone (135 mg/die) was started. Neurological and ophthalmologic follow-up, six months after diagnosis, were stable.
P3. The proband P3 is a 12 year old girl, who was born at term by dystocic delivery; she was the second child of healthy consanguineous parents. The eldest brother was healthy. She acquired autonomous ambulation at 14 months of age, but parents reported that she had always been unsteady, and had delayed speech development. At 4 years she began to present psychomotor regression, ataxia and deficient motor coordination. At 4 years the neurological examination showed an ataxic-spastic gait, nystagmus, dysmetria and dysarthria. She performed a first brain MRI which showed abnormal hyperintensities of the periventricular and centrum semiovale white matter areas in T2-weighted images bilaterally (Additional file 2). Electrophysiological examinations showed bilateral absence of the V wave at Brainstem Auditory Evoked Potentials (BAEPs), and Nerve Conduction Studies (NCS) disclosed an axonal sensory-motor neuropathy (decreased CMAP and SAP amplitudes with conduction velocities at the lower level of controls range). Phytanic and pristanic acids, VLCFA, Vitamin E, hexosaminidase A and B levels were in the normal range. One year later, the neurological conditions worsened with increased spasticity in her legs and unsteadiness during walking and postural changes. NCS showed a progressive decrease of CMAP amplitudes compared to previous values; VEP and ERG were normal. A second MRI performed at 8 years of age showed T2-hyperintense abnormal signals corresponding to both putaminal nuclei, associated with mild global cerebellar atrophy, while the abnormal areas of T2 hyperintensities of the white matter had disappeared (Additional file 2). Mutations in FXN, ATM and PLA2G6 were ruled out by Sanger sequencing. At age 10 years the neurological examination was stable; repeated flash VEP showed slightly delayed latencies bilaterally, whereas OCT was reported as normal. The last neurological evaluation at age 12 years showed an ataxic-spastic syndrome with distal muscular atrophy of upper and lower limbs. A deep ophthalmological examination was performed: OCT revealed a mild reduction of retinal nerve fiber layer in both eyes whereas flash ERG and pattern VEP responses (60’ stimuli) were in the normal range. However, an amplitude reduction of VEP response was found for 15’ stimuli: abnormalities in VEP 15’ responses, which mainly reflect macular fibers responses contributing to the temporal quadrant of the optic nerve, are quite typical of OPA1- related optic neuropathy (Additional file 3).
Targeted sequencing and variant filtering in P2 led to the identification of two heterozygous OPA1 variants: c.2962G > T (p.Val988Phe), and the recurrent c.1311A > G substitution (p.Ile437Met). Both variants were confirmed by Sanger sequencing; the mother harbored the c.1311A > G, the paternal DNA was not available for genotyping (Fig. 2b).
In P3 data annotation of WES data predicted 13229 high-quality variants having functional impact (i.e., non-synonymous, indels and splice site changes). Among them, 338 private and rare changes were retained for further analyses. Variants were prioritized on the basis of the functional relevance of genes, taking into account both dominant and recessive inheritance models. Only changes predicted to be deleterious by CADD V.1.3 (score >15.0) or dbNSFP SVM V.2.9 (radial score >0.0) algorithms were considered as candidates. Variant filtering and prioritization allowed to identify a missense homozygous variant in OPA1, c.1180G > A (NM_130837.2), predicting the p.Ala394Thr amino acid substitution, as the best candidate underlying the trait, which fitted with the documented consanguinity in the family (Fig. 2c). Consistently, no suggestive disease gene candidate with a functionally relevant de novo heterozygous variant was identified in the proband (Additional file 1).
Yeast lacking MGM1 cannot grow on non-fermentable carbon sources and develop a petite phenotype . Human OPA1 per se cannot complement yeast MGM1 deletion mutants . We therefore employed a hybrid gene comprised of the 5’ portion of MGM1 (encoding the targeting sequence and the transmembrane domain) and the 3’ portion of human OPA1 (from exon 6 to the stop codon). Haploid yeast lacking MGM1 and expressing either the wild-type hybrid gene or individual mutants, were plated at seriate dilutions in medium containing glycerol as sole carbon source (YPD). The wild type hybrid gene restored growth in YPD. Conversely, yeast expressing the p.Ala394Thr displayed a marked reduction of respiratory growth, the p.Val988Phe mutation virtually abolished the activity of the mutant allele, while the defect observed with the p.Ile437Met mutant was milder, evident only at the 10-3 dilution (Fig. 2d).
Characterization of fibroblasts carrying OPA1 mutations
Compound heterozygous mutations in OPA1 have been rarely reported, usually associated with ADOA plus phenotype [5, 6, 7, 23, 26]. A table summarizing genetic and clinical features of these cases is reported as Additional file 7. The p.Ile437Met missense variant, although not causing a phenotype per se, has been recently suggested to contribute consistently in modulating the phenotype in OPA1 compound heterozygous subjects .
The biallelic OPA1 variants found in two of our patients combine a classic OPA1 haploinsufficiency mutation (i.e. a frameshift change in P1 and a missense change, acting as a null allele in yeast, in P2), which can determine dominant isolated optic atrophy with reduced penetrance, and the missense mutation p.Ile437Met, considered hypomorphic or with very low potential pathogenicity since apparently it was not able to lead to clinical symptoms in heterozygous or even homozygous state . Instead, in P3 we found a homozygous p.Ala394Thr change; this is the second case of homozygous missense mutation in OPA1 reported to date, after the description of a patient with a severe fatal cardiomyopathy associated with the p.Leu589Arg mutation .
In accordance with a recessive mode of inheritance, the parents of our probands, each carrier of one heterozygous OPA1 variant, displayed no symptoms, with the exception of a mother harboring the p.Ile437Met variant and presenting a severe myopia; this genotype-phenotype association was previously reported . Reduced penetrance of dominant mutations, typical of ADOA, may also explain the segregation in the families but it is unlikely given the severe phenotype of these patients.
The effect of the missense mutations on growth of the yeast model seems to correlate with the clinical presentation in biallelic OPA1 mutant patients; the presence of a virtually null allele (p.Val988Phe found in P2) plus a mildly compromised allele (p.Ile437Met found in P1 and P2) or the presence of a homozygous mutation with an intermediate effect (p.Ala394Thr found in P3) probably cause a similar overall impairment in OPA1 function, resulting in the disease observed in our patients.
From a medical point of view, the most striking aspect of this study is the extremely severe presentation of P1, with an infantile lethal outcome. The same course was reported in the older brother, albeit the genetic diagnosis was not possible because of lack of available DNA. We therefore cannot exclude the presence of a different genetic defect that was the primary cause of the disease in this subject, or even in our proband. However, the extensive genetic analysis with sequencing of >100 genes associated with mitochondrial disorders makes unlikely the latter hypothesis. It is possible that additional genetic factor may have exacerbated the phenotype caused by the OPA1 mutations. Interestingly, P1 showed two homoplasmic changes in his mtDNA. The mutation m.11778G > A in MTND4 is a well-known cause of LHON, a mitochondrial disorder that leads to bilateral subacute visual failure. Rarely patients harboring the m.11778G > A show a LHON-plus phenotype; nevertheless visual impairment remains the most common presenting feature, although neurologic features have been documented in several cases, including movement disorders, multiple sclerosis–like illnesses, peripheral neuropathy, and seizures . Haplogroup J has been shown to increase the penetrance of this mutation , but our proband belonged to haplogroup T1. However, the low penetrance of the m.11778G > A in females is compatible with the homoplasmic status of the unaffected mother. The other change found in mtDNA, m.3337G > C/p.Val11Leu in MTND1, is not phylogenetically conserved, is predicted benign but it is not present in Mitomap database (http://www.mitomap.org). Valine 11 is located at the beginning of the first α-transmembrane helix of ND1 protein, and the change with leucine is not predicted to alter the transmembrane domain. Despite both mtDNA variants affected respiratory complex I, its activity was normal in patient’s samples. All these considerations did not suggest a primary pathogenic role for the two identified mtDNA variants but did not exclude a synergistic effect together with the OPA1 mutations, worsening the clinical phenotype in our patient.
Amongst the published patients with biallelic OPA1 mutations (Additional file 7), the severe neonatal-onset disorder characterized by severe optic atrophy, ataxia, hypotonia, gastrointestinal dysmotility and dysphagia, described in two siblings by Schaaf et al. , is the closest to the clinical presentation of P1 and his brother. Conversely the phenotype reminiscent of the Behr syndrome, reported in 4 cases by Bonneau et al. , was similar to that observed in P2 and P3. However, optic atrophy was evident in all the other OPA1-mutant subjects, being often the first and main symptom; in contrast, in our patients overt optic atrophy was observed later compared to most of the other neurological signs (P1 and P3) or not reported (P1’s brother and P3, untill 10 years of age). Moreover, the rapidly progressive course of P1 is reminiscent of Leigh syndrome rather than of DOA-plus or Behr syndrome. Infantile lethal outcome due to OPA1 mutations has been described for the first time very recently: a homozygous OPA1 mutation has been found in two sisters with fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy . No evidence of heart involvement was reported in our patients, but a multiorgan failure, including gastrointestinal and hepatic impairment, was observed in P1, confirming that OPA1 proper functioning is crucial not only for the optic nerve but also for several other tissues/organs. Clinical features in P3 were particularly misleading for an OPA1 related condition, with manifestations of early onset progressive spastic ataxia and sensory motor polyneuropathy, in the absence of optic atrophy. The MRI was likewise peculiar, showing early MRI abnormal hyperintensities of the white matter suggesting a leukodystrophy followed serially by a disappearance of white matter abnormalities and appearance of bilateral abnormalities in the putamen.
Our report confirms the broad complexity in the phenotypic spectrum associated with recessive OPA1 mutations that ranges from non-syndromic phenotypes overlapping with those caused by dominant OPA1 mutations to severe fatal encephalopathy resembling typical mitochondrial diseases. Moreover, our findings suggest that bi-allelic OPA1 mutations should be considered in disorder where optic atrophy is not obvious (or even absent).
OPA1 mutations should not be considered only for dominant trait or only for optic atrophy phenotypes.
We acknowledge the “Cell Lines and DNA Bank of Movement Disorders and Neurodegenerative Diseases” of the Telethon Network of Genetic Biobanks (grant GTB12001J) and the Eurobiobank Network for providing patients’ samples.
This work was supported by the Telethon Grants GGP15041, GGP13222 and GGP14187; the Italian Ministry of Health (GR2010–2316392 and RC2016), the Pierfranco and Luisa Mariani Foundation, Fondazione CARIPARO, and Bulgari.
Availability of data and materials
Patients’ samples are available upon request to the Telethon biobank (http://biobanknetwork.telethon.it).
AN, TR performed functional studies on patients’ samples. MD, CC performed yeast studies under the supervision of LS. AL, GC, EL, DD, CA, MDN performed genetic and biochemical studies. AC, MN performed WES analysis and bioinformatics under the supervision of MT. CL, AA, EB, IM diagnosed the family and performed the clinical examinations. SBM and GI performed ophthalmological examinations. DG and RC supervised all the genetic work and functional studies. AN, DG, RC, EB wrote the manuscript. All the authors critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Present in the signed informed consent for anynomized data.
Ethics approval and consent to participate
Informed consent for genetic and biochemical studies was obtained from patients’ parents, in agreement with the Declaration of Helsinki and approved by the Ethical Committees of the Neurological Institute “Besta” and “Bambino Gesù” Children Hospital.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Amati-Bonneau P, Guichet A, Olichon A, Chevrollier A, Viala F, Miot S, Ayuso C, Odent S, Arrouet C, et al. OPA1 R445H mutation in optic atrophy associated with sensorineural deafness. Ann Neurol. 2005;58:958–63.View ArticlePubMedGoogle Scholar
- Amati-Bonneau P, Valentino ML, Reynier P, Gallardo ME, Bornstein B, Boissiere A, Campos Y, Rivera H, de la Aleja JG, et al. OPA1 mutations induce mitochondrial DNA instability and optic atrophy ‘plus’ phenotypes. Brain. 2008;131:338–51.View ArticlePubMedGoogle Scholar
- Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133:771–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Pesch UEA, Leo-Kottler B, Mayer S, Jurklies B, Kellner U, Apfelstedt-Sylla E, Zrenner E, Alexander C, Wissinger B. OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance. Hum Molec Genet. 2001;10:1359–68.View ArticlePubMedGoogle Scholar
- Schaaf CP, Blazo M, Lewis RA, Tonini RE, Takei H, Wang J, Wong L-J, Scaglia F. Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations. Molec Genet Metab. 2011;103:383–7.View ArticlePubMedGoogle Scholar
- Bonneau D, Colin E, Oca F, Ferre M, Chevrollier A, Gueguen N, Desquiret-Dumas V, N’Guyen S, Barth M, et al. Early-onset Behr syndrome due to compound heterozygous mutations in OPA1. Brain. 2014;137:e301.View ArticlePubMedGoogle Scholar
- Carelli V, Sabatelli M, Carrozzo R, Rizza T, Schimpf S, Wissinger B, Zanna C, Rugolo M, La Morgia C, et al. ‘Behr syndrome’ with OPA1 compound heterozygote mutations. Brain. 2015;138:e321.View ArticlePubMedGoogle Scholar
- Spiegel R, Saada A, Flannery PJ, Burte F, Soiferman D, Khayat M, Eisner V, Vladovski E, Taylor RW, et al. Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation. J Med Genet. 2016;53:127–31.View ArticlePubMedGoogle Scholar
- He L, Chinnery PF, Durham SE, Blakely EL, Wardell TM, Borthwick GM, Taylor RW, Turnbull DM. Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res. 2002;30:e68.View ArticlePubMedPubMed CentralGoogle Scholar
- Gai X, Ghezzi D, Johnson MA, Biagosch CA, Shamseldin HE, Haack TB, Reyes A, Tsukikawa M, Sheldon CA, et al. Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. Am J Hum Genet. 2013;93:482–95.View ArticlePubMedPubMed CentralGoogle Scholar
- Legati A, Reyes A, Nasca A, Invernizzi F, Lamantea E, Tiranti V, Garavaglia B, Lamperti C, Ardissone A, et al. New genes and pathomechanisms in mitochondrial disorders unraveled by NGS technologies. Biochim Biophys Acta. 2016;1857:1326–35.View ArticlePubMedGoogle Scholar
- McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–303.View ArticlePubMedPubMed CentralGoogle Scholar
- Cordeddu V, Redeker B, Stellacci E, Jongejan A, Fragale A, Bradley TE, Anselmi M, Ciolfi A, Cecchetti S, et al. Mutations in ZBTB20 cause Primrose syndrome. Nat Genet. 2014;46:815–7.View ArticlePubMedGoogle Scholar
- Niceta M, Stellacci E, Gripp KW, Zampino G, Kousi M, Anselmi M, Traversa A, Ciolfi A, Stabley D, et al. Mutations impairing GSK3-mediated MAF phosphorylation cause cataract, deafness, intellectual disability, seizures, and a down syndrome-like facies. Am J Hum Genet. 2015;96:816–25.View ArticlePubMedPubMed CentralGoogle Scholar
- Sferra A, Baillat G, Rizza T, Barresi S, Flex E, Tasca G, D’Amico A, Bellacchio E, Ciolfi A, et al. TBCE mutations cause early-onset progressive encephalopathy with distal spinal muscular atrophy. Am J Hum Genet. 2016;99:974–83.View ArticlePubMedPubMed CentralGoogle Scholar
- Flex E, Niceta M, Cecchetti S, Thiffault I, Au MG, Capuano A, Piermarini E, Ivanova AA, Francis JW, et al. Biallelic mutations in TBCD, encoding the tubulin folding cofactor D, perturb microtubule dynamics and cause early-onset encephalopathy. Am J Hum Genet. 2016;99:962–73.View ArticlePubMedPubMed CentralGoogle Scholar
- Cingolani P, Platts A, le Wang L, Coon M, Nguyen T, Wang L, Land SJ, Lu X, Ruden DM. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 2012;6:80–92.View ArticleGoogle Scholar
- Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46:310–5.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong C, Wei P, Jian X, Gibbs R, Boerwinkle E, Wang K, Liu X. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol Genet. 2015;24:2125–37.View ArticlePubMedGoogle Scholar
- Seelow D, Schwarz JM, Schuelke M. GeneDistiller--distilling candidate genes from linkage intervals. PLoS One. 2008;3:e3874.View ArticlePubMedPubMed CentralGoogle Scholar
- Cassandrini D, Cilio MR, Bianchi M, Doimo M, Balestri M, Tessa A, Rizza T, Sartori G, Meschini MC, et al. Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients. J Inherit Metab Dis. 2013;36:43–53.View ArticlePubMedGoogle Scholar
- Rizza T, Vazquez-Memije ME, Meschini MC, et al. Assaying ATP synthesis in cultured cells: a valuable tool for the diagnosis of patients with mitochondrial disorders. Biochem Biophys Res Commun. 2009;383:58–62.View ArticlePubMedGoogle Scholar
- Bonifert T, Karle KN, Tonagel F, Batra M, Wilhelm C, Theurer Y, Schoenfeld C, Kluba T, Kamenisch Y, et al. Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier. Brain. 2014;137:2164–77.View ArticlePubMedPubMed CentralGoogle Scholar
- Nolli C, Goffrini P, Lazzaretti M, Zanna C, Vitale R, Lodi T, Baruffini E. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy. Mitochondrion. 2015;25:38–48.View ArticlePubMedGoogle Scholar
- Elachouri G, Vidoni S, Zanna C, Pattyn A, Boukhaddaoui H, Gaget K, Yu-Wai-Man P, Gasparre G, Sarzi E, et al. OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution. Genome Res. 2011;21:12–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee J, Jung SC, Hong YB, Yoo JH, Koo H, Lee JH, Hong HD, Kim SB, Chung KW, Choi BO. Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1. Mol Med Rep. 2016;14:33–40.PubMedPubMed CentralGoogle Scholar
- Paquay S, Benoit V, Wetzburger C, Cordonnier M, Meire F, Charon A, Roland D, Van Coster R, Nassogne MC, Maystadt I. Uncommon Leber “plus” disease associated with mitochondrial mutation m.11778G > A in a premature child. J Child Neurol. 2014;29:NP18–23.View ArticlePubMedGoogle Scholar
- Carelli V, Achilli A, Valentino ML, Rengo C, Semino O, Pala M, Olivieri A, Mattiazzi M, Pallotti F, et al. Haplogroup effects and recombination of mitochondrial DNA: novel clues from the analysis of Leber hereditary optic neuropathy pedigrees. Am J Hum Genet. 2006;78:564–74.View ArticlePubMedPubMed CentralGoogle Scholar